Q3 EPS Estimate for Fresenius Medical Care Lifted by Analyst

Fresenius Medical Care AG (NYSE:FMS) – Stock analysts at Zacks Research increased their Q3 2025 earnings per share estimates for shares of Fresenius Medical Care in a research note issued on Tuesday, May 27th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will earn $0.56 per share for the quarter, up from their previous estimate of $0.54. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.12 EPS, Q2 2026 earnings at $0.51 EPS, Q3 2026 earnings at $0.62 EPS, Q4 2026 earnings at $0.68 EPS, FY2026 earnings at $2.29 EPS, Q1 2027 earnings at $0.51 EPS and FY2027 earnings at $2.32 EPS.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.01. The firm had revenue of $5.54 billion during the quarter, compared to analysts’ expectations of $4.71 billion. Fresenius Medical Care had a return on equity of 6.04% and a net margin of 3.43%.

A number of other equities research analysts have also weighed in on FMS. Wall Street Zen assumed coverage on shares of Fresenius Medical Care in a research note on Tuesday, May 20th. They set a “strong-buy” rating for the company. Truist Financial lifted their price objective on Fresenius Medical Care from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, May 12th. Finally, Morgan Stanley reiterated an “underweight” rating on shares of Fresenius Medical Care in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Fresenius Medical Care presently has a consensus rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care Price Performance

FMS opened at $28.81 on Thursday. The company’s 50-day simple moving average is $25.80 and its two-hundred day simple moving average is $24.16. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The stock has a market capitalization of $16.91 billion, a P/E ratio of 23.81, a P/E/G ratio of 0.76 and a beta of 0.85. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $30.46.

Fresenius Medical Care Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be paid a dividend of $0.7871 per share. The ex-dividend date of this dividend is Friday, May 23rd. This is an increase from Fresenius Medical Care’s previous annual dividend of $0.44. This represents a dividend yield of 1.9%. Fresenius Medical Care’s payout ratio is 49.11%.

Hedge Funds Weigh In On Fresenius Medical Care

A number of hedge funds have recently modified their holdings of FMS. Wayfinding Financial LLC purchased a new position in shares of Fresenius Medical Care during the 1st quarter valued at $25,000. Spire Wealth Management purchased a new position in shares of Fresenius Medical Care in the first quarter valued at about $27,000. Smartleaf Asset Management LLC lifted its position in shares of Fresenius Medical Care by 192.8% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after acquiring an additional 806 shares in the last quarter. Brooklyn Investment Group lifted its holdings in Fresenius Medical Care by 424.5% in the 1st quarter. Brooklyn Investment Group now owns 1,285 shares of the company’s stock worth $32,000 after purchasing an additional 1,040 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Fresenius Medical Care by 234.1% in the 4th quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company’s stock worth $71,000 after purchasing an additional 2,208 shares during the period. 8.37% of the stock is currently owned by institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.